Evaluation of early musculoskeletal disease in patients with haemophilia: results from an expert consensus

por Seuser, Axel, Djambas Khayat, Claudia, Negrier, Claude, Sabbour, Adly, Heijnen, Lily
Publicado 2018

The Hemophilia Gene Therapy Patient Journey: Questions and Answers for Shared Decision-Making

por Wang, Michael, Negrier, Claude, Driessler, Frank, Goodman, Clifford, Skinner, Mark W
Publicado 2022

Emerging Immunogenicity and Genotoxicity Considerations of Adeno-Associated Virus Vector Gene Therapy for Hemophilia

por Monahan, Paul E., Négrier, Claude, Tarantino, Michael, Valentino, Leonard A., Mingozzi, Federico
Publicado 2021

Origins, Development, Current Challenges and Future Directions with Activated Prothrombin Complex Concentrate for the Treatment of Patients with Congenital Haemophilia with Inhibit...

por Brackmann, Hans H., Schramm, Wolfgang, Oldenburg, Johannes, Cano, Viridiana, Turecek, Peter L., Négrier, Claude
Publicado 2020

Decreased Bleeding Rates in Patients with Hemophilia A Switching from Standard-Half-Life FVIII to BAY 94-9027 Prophylaxis

por Mancuso, Maria Elisa, Reding, Mark T., Negrier, Claude, Kerlin, Bryce A., Rangarajan, Savita, Simpson, Mindy L.
Publicado 2021

Alpha Cyano-4-Hydroxy-3-Methoxycinnamic Acid Inhibits Proliferation and Induces Apoptosis in Human Breast Cancer Cells

por Hamdan, Lamia, Arrar, Zoheir, Al Muataz, Yacoub, Suleiman, Lutfi, Négrier, Claude, Mulengi, Joseph Kajima, Boukerche, Habib
Publicado 2013

Why patients with THBD c.1611C>A (p.Cys537X) nonsense mutation have high levels of soluble thrombomodulin?

por Jourdy, Yohann, Enjolras, Nathalie, Le Quellec, Sandra, Bordet, Jean Claude, Négrier, Claude, Vinciguerra, Christine, Dargaud, Yesim
Publicado 2017

A French multicenter randomised trial comparing two dose-regimens of prothrombin complex concentrates in urgent anticoagulation reversal

por Kerebel, Delphine, Joly, Luc-Marie, Honnart, Didier, Schmidt, Jeannot, Galanaud, Damien, Negrier, Claude, Kursten, Friedrich, Coriat, Pierre
Publicado 2013

Global Post-Authorization Safety Surveillance Study: real-world data on prophylaxis and on-demand treatment using FEIBA (an activated prothrombin complex concentrate)

por Negrier, Claude, Voisin, Sophie, Baghaei, Fariba, Numerof, Robert, Novack, Aaron, Doralt, Jennifer E., Romanov, Vadim, Gringeri, Alessandro
Publicado 2016

Patients’ Perception of the Impact of Innovation on Hemophilia Care Management Organization: A Qualitative Study Protocol (INNOVHEMO Study)

por Beny, Karen, du Sartz de Vigneulles, Benjamin, Chamouard, Valerie, Guilloux, Ronald, Gay, Valérie, Negrier, Claude, Dussart, Claude
Publicado 2021

Haemophilia in France: Modelisation of the Clinical Pathway for Patients

por Beny, Karen, du Sartz de Vigneulles, Benjamin, Carrouel, Florence, Bourgeois, Denis, Gay, Valérie, Negrier, Claude, Dussart, Claude
Publicado 2022

Multiple criteria decision analysis for therapeutic innovations in a hemophilia care center: A pilot study of the organizational impact of innovation in hemophilia care management

por Beny, Karen, Dubromel, Amélie, du Sartz de Vigneulles, Benjamin, Gay, Valérie, Carrouel, Florence, Negrier, Claude, Dussart, Claude
Publicado 2022

Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 Study

por Schmitt, Christophe, Adamkewicz, Joanne I., Xu, Jin, Petry, Claire, Catalani, Olivier, Young, Guy, Negrier, Claude, Callaghan, Michael U., Levy, Gallia G.
Publicado 2021

Continuous Infusion of Factor VIII and von Willebrand Factor in Surgery: Trials with pdFVIII LFB or pdVWF LFB in Patients with Bleeding Disorders

por Windyga, Jerzy, Guillet, Benoît, Rugeri, Lucia, Fournel, Alexandra, Stefanska-Windyga, Ewa, Chamouard, Valérie, Pujol, Sonia, Henriet, Céline, Bridey, Françoise, Négrier, Claude
Publicado 2022

Real-world data in patients with congenital hemophilia and inhibitors: final data from the FEIBA Global Outcome (FEIBA GO) study

por Ettingshausen, Carmen Escuriola, Hermans, Cedric, Holme, Pål A., Cid, Ana R., Khair, Kate, Oldenburg, Johannes, Négrier, Claude, Botha, Jaco, Lelli, Aurelia, Windyga, Jerzy
Publicado 2023

BAY 94‐9027 prophylaxis is efficacious and well tolerated for up to >5 years with extended dosing intervals: PROTECT VIII extension interim results

por Lalezari, Shadan, Reding, Mark T., Pabinger, Ingrid, Holme, Pal Andre, Negrier, Claude, Chalasani, Pavani, Shin, Ho‐Jin, Wang, Maria, Tseneklidou‐Stoeter, Despina, Maas Enriquez, Monika
Publicado 2019

Recombinant porcine factor VIII corrects thrombin generation in vitro in plasma from patients with congenital hemophilia A and inhibitors

por Négrier, Claude, Oldenburg, Johannes, Kenet, Gili, Meeks, Shannon L., Bordet, Jean‐Claude, Müller, Jens, Le Quellec, Sandra, Turecek, Peter L., Tripkovic, Nikola, Dargaud, Yesim
Publicado 2022

Confirmed long‐term safety and efficacy of prophylactic treatment with BAY 94–9027 in severe haemophilia A: final results of the PROTECT VIII extension study

por Reding, Mark T., Pabinger, Ingrid, Holme, Pal Andre, Poulsen, Lone, Negrier, Claude, Chalasani, Pavani, Maas Enriquez, Monika, Wang, Maria, Meijer, Karina, Mancuso, Maria Elisa, Lalezari, Shadan
Publicado 2021

Management of von Willebrand disease with a factor VIII‐poor von Willebrand factor concentrate: Results from a prospective observational post‐marketing study

por Goudemand, Jenny, Bridey, Françoise, Claeyssens, Ségolène, Itzhar‐Baïkian, Nathalie, Harroche, Annie, Desprez, Dominique, Négrier, Claude, Chamouni, Pierre, Chambost, Hervé, Henriet, Céline, Susen, Sophie, Borel‐Derlon, Annie
Publicado 2020

Optimizing language for effective communication of gene therapy concepts with hemophilia patients: a qualitative study

por Hart, Daniel P., Branchford, Brian R., Hendry, Sarah, Ledniczky, Robert, Sidonio, Robert F., Négrier, Claude, Kim, Michelle, Rice, Michelle, Minshall, Matthew, Arcé, Claire, Prince, Steve, Kelleher, Maria, Lee, Sharon
Publicado 2021